𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients

✍ Scribed by K. Schönholzer; C. Marone

Publisher
Springer
Year
1992
Tongue
English
Weight
258 KB
Volume
42
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

The pharmacokinetics of isradipine, a calcium-channel blocker, have been studied in eight patients on chronic haemodialysis. A single oral dose of 5 mg was administered on both a non-haemodialysis and a haemodialysis day and the plasma concentrations of isradipine were analyzed. The mean cmax, tmax, AUC, and t1/2 in plasma on the non-haemodialysis day were 5.2 ng.ml-1, 1.4 h, 23.8 ng.h.ml-1, and 3.1 h, respectively. The dialysis clearance of isradipine was negligible (5.0 ml.min-1). The t1/2 values during haemodialysis were not significantly different from those observed during the same period post dose on the non-haemodialysis day. The study demonstrates that supplemental doses of isradipine are not necessary in these patients since isradipine is not significantly removed by haemodialysis.

📜 SIMILAR VOLUMES

Pharmacokinetics of isradipine in patien
Pharmacokinetics of isradipine in patients with chronic liver disease
✍ J. Cotting; J. Reichen; K. Kutz; R. Laplanche; E. Nüesch 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 523 KB

The pharmacokinetics of the dihydropyridine calcium antagonist isradipine has been examined in 8 healthy volunteers, 7 patients with non-cirrhotic chronic liver disease (CLD), and 8 patients with biopsy-proven cirrhosis (CIR). Isradipine was simultaneously given orally (12C 5 mg) and i.v. (13C 1 mg)

Oral pharmacokinetics of pirenzepine in
Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis
✍ T. MacGregor; K. Matzek; J. Keirns; M. Vinocur; A. Chonko 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 215 KB

The pharmacokinetic properties of pirenzepine following administration of a single, 50 mg oral dose were evaluated in three groups of subjects: group I, end stage renal disease requiring maintenance haemodialysis (CLCR 0 to 10 ml.min-1); group II, moderate renal insufficiency (CLCR 10 to 30 ml.min-1

The pharmacokinetics and pharmacodynamic
The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients
✍ T. W. B. Gehr; D. A. Sica; D. M. Grasela; K. L. Duchin 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 662 KB

The pharmacokinetics and pharmacodynamics of fosinoprilat, the diacid of fosinopril sodium (a new angiotensin-converting enzyme (ACE) inhibitor), were investigated in six haemodialysis patients. Intravenous 14C-fosinoprilat (7.5 mg), oral 14C-fosinopril sodium (10 mg) and oral fosinopril sodium (10

The pharmacokinetics of fluconazole duri
The pharmacokinetics of fluconazole during haemodialysis in uraemic patients
✍ S. Oono; K. Tabei; T. Tetsuka; Y. Asano 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 199 KB

We have studied the pharmacokinetics of fluconazole in five patients on long-term haemodialysis. The single-pass extraction rate of the dialyzer was 59 (3.5)% (n = 4), and the serum concentration was reduced by haemodialysis for 3 or 4 h by 26 (3.2)% (n = 5) and 39 (2.2)% (n = 9) respectively. The e

Pharmacokinetics of intravenous and oral
Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis
✍ J. Sennesael; D. Verbeelen; L. Vanhaelst; R. Pirola; S. R. Bareggi 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 416 KB

The pharmacokinetics of a single 2 mg IV dose of chlordesmethyldiazepam has been studied in 11 patients with renal failure on regular haemodialysis and in 11 age-matched healthy controls. The kinetics was also examined after a single 2 mg oral dose in 6 of the 11 renal failure patients. After intrav